INDEX

1. INTRODUCTION ........................................................................................................................ 1
   1.1. Subject ......................................................................................................................................... 1
2. PROCEDURES ............................................................................................................................ 3
   2.1. Application access ........................................................................................................................ 3
   2.2. Vaccine marketing form ............................................................................................................... 4
   2.3. Request for clarification form. Sending the information requested for release vaccines onto
        the market (Need of increase previously requested batches) ................................................. 6
   2.4. Authorization without 5 days waiting period ............................................................................. 7
3. PROCEDURE FOR PARALLEL DISTRIBUTION APPLICATIONS .................................................. 8
1. INTRODUCTION

1.1. Subject

The purpose of this document is to produce a user’s manual for the electronic procedure for Batch Release of Vaccines onto the market.

The procedure of implementation in market of blood products and vaccines, with the implementation of the Law 10-2013, that modifies Royal Decree 1345/2007, introduces the rate 1.15 for that procedure.

Payment is made once a year to the best option according to number of annual applications.

The access is made through the following link:

- https://sede.aemps.gob.es/#pagoTelematicoTasas

Instructions for completing the form for Market Release of Vaccines for Human Use

1st Instruction

Batches of vaccines for human use shall not be placed on the market without authorization, according to the following procedure.

2nd Instruction

This provision does not extend to other immunological medicines such as toxins, serums and allergens, individualized vaccines are also excluded.

Neither does apply to foreign medicines, or products undergoing clinical trials.

3rd Instruction

Prior to the placing on the market of the product in question a request for market release will be sent to the Division of Biologics and Biotechnology (DPBB) of the Spanish Agency for Medicines and Medical Devices (AEMPS).

For this purpose it is available an electronic system set by the AEMPS for submitting applications. Accessed through the website https://www.aemps.gob.es.

The address to be connected to is the following: (It is important to type in the S after http as if not done, the connection is not made).


Communications of placing on the market of Vaccines for Human Use may be made:

- Without an electronic signature.
- By electronic signature if having a digital certificate accepted by the Ministry of Health.

4th Instruction

The application shall be accompanied by the following documentation:


- ANNEX IIA EU official control authority batch release certificate for immunological products.
- ANNEX IV Marketing information form, model for manufacturers.
• Summary of production and control protocols of lot(s) to be released, according to the administrative procedure for the Official Control Authority Batch Release and the specific product guidelines.

• An image of secondary packaging material of the finished product from the batch in question, allowing complete viewing, as well as an image of the label attached to the immediate packaging of the lot.

When applicable it must also be sent:

• ANNEX IIIG EU official control authority batch release certificate of approval for Monovalent Pneumococcal Polysaccharide bulk conjugates.

5th Instruction

After a period of 5 working days from sending the last valid documentation without a negative pronouncement, and taking into account the special need for these products, the lot is deemed approved for marketing.

In the case of seasonal flu vaccine the 5 days shall be reduced to 2.

The electronic system allows the laboratory making the request to have proof that the request has been made, and the AEMPS to be aware that the communication has been sent.

In the event that there is a computer system crash the applicant will proceed through fax (91.822.78.92), email (hemoderivados@aemps.es), or an alternative procedure.

If the application involves the performance of analysis of the lot for not having certifications noted above, the request will be resolved within a maximum period of 60 days and of 30 days for the seasonal flu vaccine.
2. PROCEDURES

In this section we find an explanation of the instructions of the procedure for Vaccines batch release.

2.1. Application access

To access the application open a web page with the address:


The initial screen opens with the Market Release and Request for Clarification forms, for both vaccines as blood-derived products.

![Initial Screen](image)

**Figure 1 - Initial Screen**

In this initial screen appears the AENOR logo and our certificate number, which indicates that the process is certified by this entity.

**Solicitud de Puesta en Mercado de Hemoderivados**: to submit a first application.

**Aclaraciones a la Puesta en Mercado de Hemoderivados**: sending the information requested and need of increase previously requested batches.

**Imprimir justificante**: search and print an application.
2.2. Vaccine marketing form

![Vaccine Marketing Form](image)

Figure 2 Vaccine Marketing Form.

- **Contact person details:**

  The applicant company must fill in the contact details of the person responsible for the application for placing on market of blood products. These data can be stored in the form of XML file, for in subsequent requests, you can load automatically without having to re-enter the information.

  For this purpose, be typed data marked with red asterisk and are saved in XML format by pressing the green arrow at the top right of the screen icon.

  In successive requests, data is loaded without typing them, by pressing the yellow arrow (beside the green arrow) and with the option to 'Examinar', seeks the saved XML file, and the data is loaded.
Application data details:

In the Application Data section, you are asked to fill in the following fields:

- Payment of Taxes Code will indicate the generated number, according to the law 10-2013, that modifies Royal Decree 1345/2007, introduces the 1.15 rate for this procedure.

There is another electronic application for payment of fees from which you can make any kind of payments to the AEMPS. This application is available at:

- [https://sede.aemps.gob.es/#pagoTelematicoTasas](https://sede.aemps.gob.es/#pagoTelematicoTasas)

An additional field is available for Parallel Distribution applications, “Presenta justificante de pago de la EMA”. In this cases It’s not necessary to submit a payment of national Taxes.

Search “Medicamento”: a sub-form opens to locate the correct product.

The search can be performed by pharmaceutical product name and / or Registration Code. Once the product is loaded, the following sections have to be filled in:

- Type of financing.
- Final Price.
- Lot Nº.
- Perforated detachable section.
- Comments.
- Dose Number (doses to be marketed).
- Expiry date.
- Releasing OMCL (OMCL performing batch release).

Upload the attachments.

As stated in Instruction 5, after 5 working days from the dispatch of the last valid documentation without negative decision (positive silence procedure), and taking into account the special needs of these products, the lot shall be deemed marketed.

In the case of seasonal flu vaccine, the 5 days shall be reduced to 2.

In the event of faults in the documentation, either because it is considered wrong or incomplete the applicant company will receive via email a "request for clarification" document formatted according to Figure 4.
As a result and until the corresponding defect is remedied, the product cannot be placed on the market. Once the problem is fixed, after sending the required documentation, the set time (5 working days) should be awaited, provided that there is no additional information required.

2.3. Request for clarification form. Sending the information requested for release vaccines onto the market (Need of increase previously requested batches)

In the same way as the initial application, but selecting the link "Clarifications for Batch Release of Blood Products" ("Aclaraciones a la puesta en mercado de hemoderivados") rather than "New application".

This will load the following screen:

Figure 5 - Clarification Form for the Batch Release of Vaccines.
To submit the clarifications the applicant company has to provide the code of the application to which the clarifications are associated with and to load from the XML data file information such as contact details of the person making the marketing application and the clarification data itself. Likewise it allows to attach new documentation if needed.

- In the case of documentation to remedy by mistake in the initial request, will select the option "New file" and is displayed on the tab that the document appears.

- In the case of need of increase previously requested batches, the "New file" option is selected, a new document “Marketing Information Form” is required (annex IV) specifying the additional number of units of the lot.

From this point the procedure is the same again: after the 5 working days period (2 days for seasonal flu) from sending the last valid documentation without negative decision (positive silence procedure), and taking into account the special need for these products, the lot shall be deemed marketed.

2.4. Authorization without 5 days waiting period

Taking into account the potential situations of the special needs of these products, may be the case that the Company make a request not to wait the five working days that the procedure requires.

After reviewing the documentation, if it is correct and if applicable, the BP Division will send to the Company (positive pronouncement) a document authorizing the placing on the market of the batch product concerned, without having to wait the 5 days period specified in the procedure.

![Authorization form without 5 days waiting period](image)
3. PROCEDURE FOR PARALLEL DISTRIBUTION APPLICATIONS

The Procedure starts when the parallel distributor (pharmaceutical company independent of the marketing-authorization holder) wants to market a centrally authorized medicinal product from one Member State to Spain.

Before placing a product on the national market the Parallel Distributor should send a request to DPBB by mail indicating the trade name and batch number of the vaccine to be distributed, as well as the country of origin. The DPBB will contact with the OMCL of this country of origin asking for a copy of the ANNEX IIA EU official control authority batch release certificate for immunological products. Once received, the parallel distributor will be informed that an application should be submitted and the OMCL who signs the European Certified. In this case it is not necessary the payment of national taxes and, as is stated in Figure 2, by clicking the "Presenta justificante de pago de la EMA" box.

The documents required in this case are:

- Marketing Information Form, adapted for this purpose (Illustration 7).
- Accreditation form issued by the AEMPS, that allows the parallel distributor carry out these activities.
- Accreditation form issued by the AEMPS Department of Inspección y Control.
- Accreditation fee paid to the Agency (EMA) for checking that the conditions laid down in Union legislation on medicinal products.
- An image of secondary packaging material of the finished product from the batch in question, allowing complete viewing, as well as an image of the label attached to the immediate packaging of the lot. I should be visible the name and the Company address, the Código Nacional with the IP mention, which indicate on the packaging that the medicinal product is being marketed by parallel distribution.

The rest of the procedure is carried out in the same way as the rest of the requests, with five days of positive silence and the option of clarification where appropriate.